The aim of this study was to evaluate the local immune status of human ovarian cancers by the comprehensive analysis of tumor-infiltrating immune cells and immunosuppressive factors, and to elucidate the local immunity in clinical course. The numbers of CD1 +, CD4+, CD8+, CD57+, forkhead box P3+ and programmed cell death-1+ cells were counted, and the intensity of immunosuppressive factors, such as programmed cell death-1 ligand (PD-L)1 , PD-L2, cyclooxygenase (COX)-1, COX-2 and 1, were evaluated in 70 ovarian cancer specimens stained by immunohistochemistry. Then hierarchical clustering of these parameters showed the four clusters into ovarian cancer cases. Cluster 1, which had significantly better prognosis than the others, was characterized by high infiltration of CD4+ and CD8+ cells. In conclusion the comprehensive analysis of local immune status led to subdivide ovarian cancers into groups with better or worse prognoses and may guide precise understanding of the local immunity.
Introduction
Ovarian cancer is the most lethal gynecologic cancer in the world with >200,000 patients diagnosed every year and over a half of them dying annually. These deaths are partly due to the fact that more than half of the patients with ovarian cancer are diagnosed at advanced tumor stages (stage III or IV). Although platinum or taxane-based chemotherapies are effective in the treatment of the majority of ovarian cancer cases, most of the patients suffer from recurrence and eventually develop chemo-resistance. Considering the high mortality rate of ovarian cancer due to the absence of curative treatment in the advanced stage or at recurrence, new therapeutic modalities other than chemotherapy and surgery are urgently needed [1; 2; 3] .
Tumor immune therapy has long been considered as an alternative modality in the treatment of solid tumors including ovarian cancer. Nevertheless, there have been few reports on clinically successful immune therapies. The failure in immune therapies in such clinical trials is partly ascribed to the phenomenon designate that the dynamic interaction between tumor cells and immune cells in the local microenvironment plays a pivotal role in cancer development and progression [4] . In the case of advanced cancers, tumor cells establish an immunosuppressive environment regionally and make it difficult to induce immune activation to eliminate cancer cells. In this situation, adoptive immunotherapy, such as a tumor vaccine, is not sufficient to eradicate tumors [5; 6] .
The differences in the phenotypes or populations of tumor-infiltrating immune cells, such as CD4+ (helper) T cells, CD8+ (cytotoxic) T cells, CD57+ (NK) cells and CD11c+ (dendritic) cells, have been shown to be associated with different clinical outcomes of solid tumors including colorectal cancer [7] , breast cancer [8] , gastric cancer [9; 10] , lung cancer [11; 12] , hepatic cancer [13; 14] , melanoma [15] , kidney cancer [16] and uterine cervical cancer [17] . In ovarian cancer, several recent studies have shown an association between tumor-infiltrating immune cells and clinical outcomes [18; 19] . We also reported that CD8+ T cell infiltration [20] and NK cell infiltration [21] are associated with a favorable prognosis in the ovarian cancer patient.
On the other hand, regulatory T cells, most specific marker of which is FOXP3, in the tumor site play a suppressive role in the local tumor immunity, leading to tumor progression [22; 23] .
With respect to the tumor, there are also a wide variety of mechanisms that enable tumor cells to evade an immune attack. These mechanisms include a loss of MHC [24] , the upregulation of immunosuppressive factors, such as transforming ( ) [25] , IL-10, indoleamine 2,3-dioxygenase (IDO) [26] and cyclooxygenases (COX-1 and COX-2) [27] or upregulating negative regulatory signals, such as programmed cell death-1 (PD-1) ligands (PD-L1, PD-L2) and cytotoxic T lymphocyte antigen-4 (CTLA-4) [28; 29; 30; 31] . We reported that PD-L1 expression in ovarian cancer is inversely correlated with tumor-infiltrating CD8+ T cells and is associated with a poor prognosis of the patient [20] . The expression of the immune suppressive factors COX and UL-16 binding protein 2 is also inversely associated with CD8+ T cell infiltration and the prognosis of the patient with ovarian cancer [21; 32] .
Thus, there are a variety of reports that suggest that a certain immunosuppressive factor influences the local tumor immunity. However, there are few comprehensive analyses that integrate various immune factors and evaluate the immune status as a whole.
Therefore, in this study, we attempted to explore the status of local immunity in ovarian cancers by integrating various immune parameters presented by the immunohistochemical analysis of clinical specimens. For this purpose, we employed bioinformatics analyses, such as hierarchical clustering, that allows the comprehensive assessment of multiple factors and enables us to determine the relationships among them. 
Materials and Methods

Patients and Samples
Immunohistochemistry
The primary antibodies and antigen retrieval methods are listed in Supplementary were incubated with biotinylated rabbit anti-mouse secondary Abs (Nichirei), followed by an incubation with a streptavidin-peroxidase complex solution. Signals were generated by incubation with 3, 3-diaminobenzidine. Finally, the sections were counterstained with hematoxylin and observed under a microscope.
Evaluation of the specimens
Immune cells in the intraepithelial space were counted using a microscopic field at ×200 magnification (0.0625 mm 2 ). Five areas with the most abundant infiltration of immune cells were selected, and an average count was calculated. The result was interpreted as negative when fewer than five cells per 0.0625 mm 2 were observed and as was evaluated according to the intensity of the staining and scored as follows: 0, negative; 1, very weak expression; 2, moderate expression; and 3, strongest expression.
Cases with scores of 0 or 1 were defined as the low-expression group, and cases with scores of 2 or 3 were defined as the high-expression group. Two independent gynecological pathologists examined the immunohistochemical slides without any prior information regarding the clinical history of the patients.
Hierarchical clustering and statistics
Hierarchical clustering analysis of our immunohistochemical data was performed using the software Cluster 3.0 that was originally designed for manipulating cDNA microarray data [33] . Following the instructions of the software, the eleven parameters (six tumor-infiltrating immune cells and five immune suppressive factors) were normalized, and a complete-linkage hierarchical clustering was conducted. The dendrogram and heat map were graphically viewed using Java TreeView [33] . Cluster and Treeview software are freely available programs that can be accessed at http://jtreeview.sourceforge.net/.
Statistical analysis
each cluster and various clinicwas employed to analyze the associations among 11 immunological factors. Univariate analysis for overall survival was performed and evaluated with the log rank test, and Kaplan Meier curves were generated. A multivariate Cox proportional-hazard model was used to evaluate the independency of Cluster 1 as a prognostic factor. Two-sided P values of <0.05 were considered to be significant.
Results
Expression of immune-suppressive factors in ovarian cancer specimens and patient prognosis
Immunohistochemical expression of 1, PD-L1, PD-L2, COX-1 and COX-2
were evaluated in 70 ovarian cancer tissues ( Figure 1 ). High expression (score 2 or 3) of 1 was observed in 22 cases (31.4%) and low expression (scored 0 or 1) was observed in 48 cases (68.6%). There was no correlation between the expression of these factors and clinicopathological characteristics such as age, histological type, FIGO stage, TNM classification, and residual tumor state ( Supplementary Table 2 ) [20; 32] .
The log rank test showed that the 5-year survival rate of patients with high expression of 1, COX-1 or COX-2 was not significantly different from the patients with low expression ( Supplementary Figure 1 ). Only the high expression of PD-L1 was an independent worse prognostic factor, whereas PD-L2 expression was not related to patient prognosis [20] .
Tumor-infiltrating immune cell count and prognosis
The number of tumor-infiltrating CD1 + (dendritic cells), CD4+ (helper T cells),
CD8+ (killer T cells), CD57+ (NK cells), FOXP3+ (regulatory T cells) and PD-1+
immune cells was evaluated using the same 70 ovarian cancer specimens ( Figure 1 ).
The average numbers of these cells were shown in Supplementary Table 3 , respectively.
There was positive correlation between tumor-infiltrating FOXP3+ cells and several
clinicopathological factors such as age, histology, tumor status and residual tumor, while there was no correlation between the number of CD4+, CD8+, CD57+ or PD-1+ cells and clinicopathological characteristics (Supplementary Table 4 and 5). The log rank test showed that the overall survival rate of patients with high levels of CD1 +, CD4+, CD57+, FOXP3+ or PD-1+ immune cells was not significantly different from patients with low infiltration ( Supplementary Figure 1) , whereas a high infiltration of CD8+ cells was the only beneficial prognostic factor (p<0.001) [20] .
Combination of any two factors such as CD8+ and PD-L1 low did not serve as a superior prognostic factor compared with single factor. Besides we found a higher ratio of CD8/FOXP3 in Cluster 1 than that in Cluster 2-4, although there was no statistic significance (mean ± SD, Cluster 1, 3.4±2.4 vs. Cluster 2-4, 1.9±1.9 ).
The correlation among eleven immunological factors
The correlation among eleven immunological factors (the expression of PD-L1, PD-L2, COX-1, COX-2 and 1 and the number of tumor-infiltrating immune cells expressing CD1 +, CD4+, CD8+, CD57+, FOXP3+ and PD-1+) was examined (Supplementary Table 6 ). The expression of PD-L1 or COX expression was negatively correlated with the number of CD8+ cells in the tumor site, respectively [20; 32] . In this study, we found that the number of CD4+ cells was positively correlated with the number of CD8+ cells (correlation coefficient (R=0.240; p=0.045) and FOXP3+ cells (R=0.410; p<0.001). In addition, the number of PD-1+ cells showed a positive correlation with the number of CD4+ cells (R=0.302; p=0.011), CD8+ cells (R=0.366; p=0.002) and CD57+ cells (R=0.365; p=0.002). The number of FOXP3+ cells was negatively correlated with PD-L2 expression (R=-0.262; p=0.028). and high COX-2 (Figures 3 and 4 ).
Evaluation of the local immune status by hierarchical clustering of immune factors in ovarian cancer
Univariate analysis and correlation between four clusters and clinicopathological factors
The Kaplan Meier curve and log rank test showed that the overall survival rate of patients in Cluster 1 was significantly better than those in the other clusters (5-year survival rate in Cluster 1 vs. Clusters 2-4, 84.6% vs. 55.2%; p=0.041) ( Figure 5 and Table 1 ). The progression-free survival rate of patients in Cluster 1 was not significantly, but was relatively, better than other clusters (5-year survival rate of Cluster 1 vs.
Clusters 2-4, 78.6% vs. 44.4%; p=0.061).
There was no statistical correlation between the four clusters and the clinicopathological factors such as primary tumor status, lymph node metastasis, distant metastasis, residual tumor status, the age of the patient, histology, and adjuvant chemotherapy ( Table 2 ).
Multivariate analysis
Multivariate analysis showed that Cluster 1 was an independent favorable prognostic factor for overall survival (RR, 4.93) ( 
Discussion
Recent studies have shown that local tumor immunity is closely associated with clinical course of cancer patient, and several immunological factors, including CD8 T cell count shown in our previous study, serve as prognostic indicator. However, these analyses were mainly done using single factor or combination of several factors, and there are few papers which tried to clarify the immunological background by analyzing multiple immune factors simultaneously. The application of hierarchical clustering allowed us to manage the complex data sets of immunohistochemical staining with multiple antibodies [34; 35] and to identify new groups of patients with similar local immunological patterns that may be caused by similar consequences. Ovarian cancers were divided into two groups, Cluster 1 and Clusters 2-4, by hierarchical clustering analysis according to the local immunological state. The patients in Cluster 1 had a significantly better prognosis than those in other clusters (p=0.041, Figure 5B ). In this group, immune cells, including CD4+ cells, CD8+ cells and PD-1+ cells, were highly infiltrated into tumor sites compared to the other clusters (p=0.004, p<0.001 and p=0.0037, respectively), while the expression of 1, PD-L1, PD-L2, COX-1 and COX-2 were significantly low. In this group, PD-1+ cells may represent T cells in the late active phase [36] , though its significance is to be clarified. Thus, Cluster 1 was characterized by high immune cell infiltration and low expression of all immunosuppressive factors studied (Figures 3 and 4 ), suggesting that host-tumor immunity in the tumor microenvironment is still maintained in this group, which may lead to the significantly better prognosis. Besides a ratio of CD8/FOXP3ratio in Cluster 1 was higher than that in Cluster 2-4, although there was no statistic significance, which is a similar tendency to the previously published report [19] .
Clusters 2-4 were characterized by a low level of immune cell infiltration and
high expression of immunosuppressive factors and had significantly worse prognoses than Cluster 1. Cluster 2 was characterized by a significantly high expression of COX-1,
whereas Cluster 3 and 4 had significantly high expressions of COX-2 (p=0.0053 and p=0.0048, respectively). The immunoregulatory function of COX-2-induced prostaglandin E2 (PGE 2 ) is known to be important in inducing immune tolerance in the tumor microenvironment [37] . Secreted from tumor cells, PGE 2 alters the Th1/Th2 balance, suppresses lymphocyte proliferation, and regulates the function of antigen presenting cells [37; 38] . There is a report that expression of COX-2 is an independent prognostic factor in human ovarian carcinoma [39] . Hence, high expression of COX-2
in Cluster 3 and Cluster 4 may contribute to poorer prognosis associated with low CD8+ cell infiltration (Figures 3-5 and Supplementary Table 6 ). Similarly, COX-1 expression was inversely correlated with CD8+ cell infiltration in Cluster 2, which may partly explain the poor prognosis of Cluster 2. This study may also provide a future direction for order-made immunotherapy in each ovarian cancer patient. Currently, therapeutic modalities to target specific immunosuppressive factors are being developed. Blocking antibodies against PD-1 (MDX-1106) have been developed and are in Phase I clinical trials for advanced refractory malignancies [41] . Phase II and III clinical trials using selective COX2
inhibitors, celecoxib and rofecoxib, in combination with a chemotherapeutic have shown a clinical benefit [42] . Clinical trials focusing on the inhibition of the signaling pathway by a monoclonal antibody or a small molecule inhibitor of the TGF receptor I kinase are being performed. To select the most efficient single or combined immune targeting therapies, precise assessments with multiple immune parameters in each case is essential.
In conclusion, hierarchical clustering of tumor-infiltrating immune cells and immunosuppressive factors was used to identify a subgroup of ovarian cancer patients with a better prognosis. This study also suggested that immunosuppressive factors might influence the pattern of tumor-infiltrating immune cells. The approach to comprehensively analyze multiple immune factors shown here may lead to a precise understanding of the local immune status and provide a tool for the application of immune therapies to treat ovarian cancer patients. 
Figure 5
Overall survival analyses of patients with ovarian cancer according to the four clusters.
(A) Kaplan-Meier curves according to Cluster 1 and the other clusters.
(B) Kaplan-Meier curves according to Cluster 1 and the combination of other clusters.
Supplementary Figure 1
Overall survival analyses of patients with ovarian cancer according to each immunological factor.
Kaplan-Meier curves according to the expression of the immunosuppressive factors (A)
TGFβ1, (B) COX-1, and (C) COX-2 and to the number of (D) CD1α+ cells, (E) CD4+
cells, (F) CD57+ cells, (G) FOXP3+ cells and (H) PD-1+ cells infiltrating into tumor
site Supplementary Table 1 Primary antibodies used for immunohistochemistry. Supplementary Table 3 The average numbers of tumor-cells, CD4+cells, CD8+cells, CD57+cells, FOXP3+cells or PD-1+ immune cells was counted using the same 70 ovarian cancer specimens. 
Supplementary Table 5 Correlations between tumor-infiltrating FOXP3+ cells or PD-1+ cells and clinicopathological characteristics in ovarian cancer (n = 70)
